Desloratadine as Adjunct Therapy for Rheumatoid Arthritis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Rheumatoid Arthritis (RA), Rheumatoid Arthritis

In brief

Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease. The purpose of this study is to evaluate the effectiveness and safety of adding desloratadine to standard therapy in patients with active rheumatoid arthritis. Participants will receive either desloratadine or placebo in addition to their usual treatment. The study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether desloratadine could be a useful add-on treatment option for patients with rheumatoid arthritis.

Key facts

Study ID
NCT07632872
Run by
Horus University
People needed
60
Starts
2026-05-23
Expected to finish
2027-01-01
Last updated by the study team
2026-06-08

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.